https://www.pharmaradar360.com/article/union-bancaire-privee-ubp-sa-sells-44-839-shares-of-teva-pharmaceutical-industri-c89c52883c078968Pharma Surgeen2026-06-27T11:00:15.000ZUnion Bancaire Privee UBP SA Sells 44,839 Shares of Teva Pharmaceutical Industries Ltd. $TEVAhttps://www.pharmaradar360.com/article/teva-pharmaceutical-industries-ltd-teva-shares-sold-by-sterling-capital-manageme-8c72506783064b85Pharma Surgeen2026-06-27T10:20:02.000ZTeva Pharmaceutical Industries Ltd. $TEVA Shares Sold by Sterling Capital Management LLChttps://www.pharmaradar360.com/article/pfizer-s-seagen-bet-sours-further-china-debate-continues-to-heat-up-and-more-6a355cec07ee49bcPharma Surgeen2026-06-27T10:00:00.000ZPfizer’s Seagen bet sours further; China debate continues to heat up; and morehttps://www.pharmaradar360.com/article/depo-provera-risks-fda-warnings-and-legal-concerns-d358b4cb35c3a531Pharma Surgeen2026-06-27T09:39:03.000ZDepo-Provera: Risks, FDA Warnings and Legal Concernshttps://www.pharmaradar360.com/article/fda-cracks-down-on-illegal-gutkha-adulterated-food-in-pune-198-raids-84-lakh-wor-c266c874b5627814Pharma Surgeen2026-06-27T09:37:52.000ZFDA Cracks Down On Illegal Gutkha & Adulterated Food In Pune; 198 Raids, ₹84 Lakh Worth Of Gutkha Seized, 92https://www.pharmaradar360.com/article/lupin-secures-us-fda-tentative-approval-for-enzalutamide-tablets-483fb27a549ab126Pharma Surgeen2026-06-27T09:14:37.000ZLupin Secures US FDA Tentative Approval for Enzalutamide Tabletshttps://www.pharmaradar360.com/article/price-to-sales-forward-of-sunhawk-vision-biotech-inc-tpex-7759-4290e94c6ded85ecPharma Surgeen2026-06-27T08:32:31.000ZPrice to sales forward of Sunhawk Vision Biotech, Inc. – TPEX:7759https://www.pharmaradar360.com/article/guangzhou-baiyunshan-pharmaceutical-holdings-company-limited-class-h-actuals-est-0dce19bc3291a468Pharma Surgeen2026-06-27T08:02:28.000ZGuangzhou Baiyunshan Pharmaceutical Holdings Company Limited Class H Actuals & Estimates (HKEX:874)https://www.pharmaradar360.com/article/price-to-book-forward-of-veraxa-biotech-ag-fwb-j8l0-a6fdf89706035a17Pharma Surgeen2026-06-27T05:55:10.000ZPrice to book forward of Veraxa Biotech AG – FWB:J8L0https://www.pharmaradar360.com/article/haisco-pharmaceutical-group-co-ltd-class-a-actuals-estimates-szse-002653-6fe22a422fee619ePharma Surgeen2026-06-27T04:50:00.000ZHaisco Pharmaceutical Group Co. Ltd. Class A Actuals & Estimates (SZSE:002653)https://www.pharmaradar360.com/article/price-to-book-forward-of-sunway-biotech-co-ltd-tpex-1271-8a987b152cd1ef79Pharma Surgeen2026-06-27T03:53:17.000ZPrice to book forward of SunWay Biotech Co., Ltd. – TPEX:1271https://www.pharmaradar360.com/article/price-to-earnings-forward-of-purple-biotech-ltd-nasdaq-ppbt-a2813785f8783f30Pharma Surgeen2026-06-27T02:10:06.000ZPrice to earnings forward of Purple Biotech Ltd. – NASDAQ:PPBThttps://www.pharmaradar360.com/article/price-to-earnings-forward-of-cell-biotech-co-ltd-krx-049960-a659745f379cc5b4Pharma Surgeen2026-06-27T02:09:37.000ZPrice to earnings forward of Cell Biotech Co., Ltd – KRX:049960https://www.pharmaradar360.com/article/enterprise-value-to-ebitda-forward-of-ildong-pharmaceutical-co-ltd-krx-249420-d649922185b47b33Pharma Surgeen2026-06-27T01:59:46.000ZEnterprise value to EBITDA forward of Ildong Pharmaceutical Co., Ltd. – KRX:249420https://www.pharmaradar360.com/article/enterprise-value-to-ebit-forward-of-ildong-pharmaceutical-co-ltd-krx-249420-74ad3dbfac9eb848Pharma Surgeen2026-06-27T01:52:21.000ZEnterprise value to EBIT forward of Ildong Pharmaceutical Co., Ltd. – KRX:249420https://www.pharmaradar360.com/article/enterprise-value-to-revenue-forward-of-cell-biotech-co-ltd-krx-049960-3d8366c87ad6656ePharma Surgeen2026-06-27T01:15:25.000ZEnterprise value to revenue forward of Cell Biotech Co., Ltd – KRX:049960https://www.pharmaradar360.com/article/enterprise-value-to-revenue-forward-of-ildong-pharmaceutical-co-ltd-krx-249420-4e1280a11dfc637ePharma Surgeen2026-06-27T00:51:28.000ZEnterprise value to revenue forward of Ildong Pharmaceutical Co., Ltd. – KRX:249420https://www.pharmaradar360.com/article/natera-ntra-partners-with-eledon-to-put-prospera-into-phase-3-kidney-trial-eb3188c243cacf4cPharma Surgeen2026-06-27T00:22:03.000ZNatera (NTRA) Partners With Eledon To Put Prospera Into Phase 3 Kidney Trialhttps://www.pharmaradar360.com/article/redwire-rdw-unveils-octopus-e140-and-completes-iss-biotech-missions-e5ba805e9c0f8170Pharma Surgeen2026-06-27T00:15:00.000ZRedwire (RDW) Unveils Octopus E140 And Completes ISS Biotech Missionshttps://www.pharmaradar360.com/article/natco-records-e2-82-b9816-9-crore-consolidated-revenue-and-e2-82-b9269-0-crore-o-7f3c019b2a7e1fd3Pharma Surgeen2026-06-27T00:00:00.000Znatco records %e2%82%b9816 9 crore consolidated revenue and %e2%82%b9269 0 crore of profit after tax for q4 fy26 and %e2%82%b94375 9 crore of revenue %e2%82%b91418 5 crore profit after tax for fy26https://www.pharmaradar360.com/article/natco-records-e2-82-b9705-4-crore-consolidated-revenue-and-e2-82-b9151-3-crore-o-3383d19ac7ba9062Pharma Surgeen2026-06-27T00:00:00.000Znatco records %e2%82%b9705 4 crore consolidated revenue and %e2%82%b9151 3 crore of profit after tax for q3fy26https://www.pharmaradar360.com/article/natco-records-e2-82-b91463-crore-consolidated-revenue-and-e2-82-b9517-9-crore-of-349810e9d31d27fbPharma Surgeen2026-06-27T00:00:00.000Znatco records %e2%82%b91463 crore consolidated revenue and %e2%82%b9517 9 crore of profit after tax for q2fy26https://www.pharmaradar360.com/article/natco-receives-tentative-approval-for-erdafitinib-tablets-generic-of-balversa-fr-1d57a0866be0fb02Pharma Surgeen2026-06-27T00:00:00.000Znatco receives tentative approval for erdafitinib tablets generic of balversa from the united states food and drug administration u s fdahttps://www.pharmaradar360.com/article/natco-receives-approval-from-central-drug-standard-control-organisation-cdsco-fo-7f97224b3c4f44d4Pharma Surgeen2026-06-27T00:00:00.000Znatco receives approval from central drug standard control organisation cdsco for semaglutide in indiahttps://www.pharmaradar360.com/article/natco-pharma-limited-api-unit-in-chennai-receives-establishment-inspection-repor-3e7000084d53fd17Pharma Surgeen2026-06-27T00:00:00.000Znatco pharma limited api unit in chennai receives establishment inspection report eir from u s fdahttps://www.pharmaradar360.com/article/natco-pharma-launches-semaglutide-generic-injection-multi-dose-vials-in-india-at-4b74d4aa0bf0444fPharma Surgeen2026-06-27T00:00:00.000Znatco pharma launches semaglutide generic injection multi dose vials in india at the most affordable price starting from mrp inr 1290https://www.pharmaradar360.com/article/natco-announces-launch-of-pomalidomide-capsules-generic-of-pomalyst-in-the-u-s-m-ab99f945b3435a7ePharma Surgeen2026-06-27T00:00:00.000Znatco announces launch of pomalidomide capsules generic of pomalyst in the u s markethttps://www.pharmaradar360.com/article/natco-announces-launch-of-its-everolimus-tablets-1-mg-generic-of-zortress-74ced45085860153Pharma Surgeen2026-06-27T00:00:00.000Znatco announces launch of its everolimus tablets 1 mg generic of zortresshttps://www.pharmaradar360.com/article/natco-and-lupin-receive-approval-from-u-s-fda-for-eribulin-mesylate-injection-f0f3544aadb9ef20Pharma Surgeen2026-06-27T00:00:00.000Znatco and lupin receive approval from u s fda for eribulin mesylate injectionhttps://www.pharmaradar360.com/article/intimation-under-regulation-30-of-sebi-listing-obligations-and-disclosure-requir-5f0ad0a9bb90a8e4Pharma Surgeen2026-06-27T00:00:00.000Zintimation under regulation 30 of sebi listing obligations and disclosure requirements regulations 2015 2https://www.pharmaradar360.com/article/disclosure-under-regulation-30-of-the-sebi-listing-obligations-and-disclosure-re-bad0ce07787d2e92Pharma Surgeen2026-06-27T00:00:00.000Zdisclosure under regulation 30 of the sebi listing obligations and disclosure requirements regulations 2015https://www.pharmaradar360.com/article/adcock-ingram-completes-delisting-from-jse-natco-pharma-acquires-35-75-stake-42b5fd02355c7a95Pharma Surgeen2026-06-27T00:00:00.000Zadcock ingram completes delisting from jse natco pharma acquires 35 75 stakehttps://www.pharmaradar360.com/article/home-page-89582f3666414b50Pharma Surgeen2026-06-27T00:00:00.000ZHome pagehttps://www.pharmaradar360.com/article/the-italian-landscape-of-digital-therapeutics-in-a-european-context-13645a6ddb3f123bPharma Surgeen2026-06-27T00:00:00.000ZThe Italian landscape of digital therapeutics in a European contexthttps://www.pharmaradar360.com/article/pharmacological-characterization-of-sll-022ccp-a-selective-opioid-receptor-agoni-35fb0ddc7d8627f3Pharma Surgeen2026-06-27T00:00:00.000ZPharmacological Characterization of SLL-022CCP, a Selective κ‑Opioid Receptor Agonist with Potent Antinociceptive Effects and Low Central Side Effectshttps://www.pharmaradar360.com/article/next-generation-trem2-targeted-therapies-for-alzheimer-s-disease-insights-and-di-074d26d71d7f952fPharma Surgeen2026-06-27T00:00:00.000ZNext-generation TREM2-targeted therapies for Alzheimer's disease: insights and directions from the INVOKE-2 trialhttps://www.pharmaradar360.com/article/loeffler-s-endocarditis-complicating-crohn-s-disease-associated-hypereosinophili-d3b7940d9126c2f4Pharma Surgeen2026-06-27T00:00:00.000ZLoeffler's endocarditis Complicating Crohn's Disease-Associated Hypereosinophilia: A Fatal Case of Eosinophil-Mediated Restrictive Cardiomyopathyhttps://www.pharmaradar360.com/article/feasibility-of-a-community-centred-approach-to-mapping-alcohol-outlet-density-an-0a7460e48c30821aPharma Surgeen2026-06-27T00:00:00.000ZFeasibility of a community-centred approach to mapping alcohol outlet density and outlet trading times in two South African communitieshttps://www.pharmaradar360.com/article/smoking-induced-liver-injury-and-related-diseases-molecular-mechanisms-pathogeni-4f32a8e951fc9c25Pharma Surgeen2026-06-27T00:00:00.000ZSmoking-induced liver injury and related diseases: Molecular mechanisms, pathogenic amplification, and clinical implicationshttps://www.pharmaradar360.com/article/new-onset-diabetes-mellitus-after-distal-pancreatectomy-incidence-predictors-and-2ddf00afa4fd0fd2Pharma Surgeen2026-06-27T00:00:00.000ZNew-onset diabetes mellitus after distal pancreatectomy: Incidence, predictors and clinical impacthttps://www.pharmaradar360.com/article/clinical-features-diagnosis-and-treatment-of-colorectal-cap-polyposis-f5701edfcbecb83cPharma Surgeen2026-06-27T00:00:00.000ZClinical features, diagnosis, and treatment of colorectal cap polyposishttps://www.pharmaradar360.com/article/a-clinical-study-on-patterns-of-vernal-keratoconjunctivitis-among-children-in-ru-0a5bbb084aa6349bPharma Surgeen2026-06-27T00:00:00.000ZA clinical study on patterns of vernal keratoconjunctivitis among children in rural part of North-East Indiahttps://www.pharmaradar360.com/article/assessment-of-health-related-quality-of-life-and-drug-related-problems-in-cardio-dd46397e1f288a6fPharma Surgeen2026-06-27T00:00:00.000ZAssessment of Health-Related Quality of Life and Drug-Related Problems In Cardiometabolic Patients In A Tertiary Care Hospitalhttps://www.pharmaradar360.com/article/the-impact-of-electronic-media-marketing-on-startup-growth-and-sustainability-285452ad2761fabbPharma Surgeen2026-06-27T00:00:00.000ZThe Impact Of Electronic Media Marketing On Startup Growth And Sustainabilityhttps://www.pharmaradar360.com/article/brand-building-in-the-digital-age-the-role-of-social-media-engagement-and-influe-16e0b04ca61b1643Pharma Surgeen2026-06-27T00:00:00.000ZBrand Building In The Digital Age: The Role Of Social Media Engagement And Influencer Marketinghttps://www.pharmaradar360.com/article/climate-smart-agriculture-and-sustainable-farming-practices-in-bastar-chhattisga-081b905b9a87d0b2Pharma Surgeen2026-06-27T00:00:00.000ZClimate-Smart Agriculture and Sustainable Farming Practices in Bastar, Chhattisgarh: Assessing Farmers’ Attitudes Toward Technology Adoptionhttps://www.pharmaradar360.com/article/quality-by-design-based-development-of-clindamycin-and-curcumin-drug-loaded-lipo-06fb382a7859c6c5Pharma Surgeen2026-06-27T00:00:00.000ZQuality by Design-Based Development of Clindamycin and Curcumin Drug-Loaded Lipospheres for Improved Topical Delivery and Antibacterial Efficacyhttps://www.pharmaradar360.com/article/witness-protection-in-india-legislative-deficit-empirical-dimensions-comparative-8b6a94e7e3b64404Pharma Surgeen2026-06-27T00:00:00.000ZWitness Protection In India: Legislative Deficit, Empirical Dimensions, Comparative Models, And The Imperative Of Parliamentary Legislationhttps://www.pharmaradar360.com/article/early-hypotonia-as-a-presentation-of-evolving-spastic-palsy-a-case-report-b824cdb55a668cb8Pharma Surgeen2026-06-27T00:00:00.000ZEarly Hypotonia as a Presentation of Evolving Spastic Palsy - A case reporthttps://www.pharmaradar360.com/article/non-pharmacological-behavior-management-techniques-in-pediatric-dentistry-a-narr-97f2c054f1d7ee10Pharma Surgeen2026-06-27T00:00:00.000ZNon-pharmacological behavior management techniques in pediatric dentistry: A narrative&amp;amp;nbsp;&amp;lt;span style=&amp;quot;font-size: 1rem;&amp;quot;&amp;gt;review and clinical insights&amp;lt;/span&amp;gt;https://www.pharmaradar360.com/article/romanian-national-study-on-the-epidemiology-of-inflammatory-bowel-diseases-3b7fbe0ea9d438b1Pharma Surgeen2026-06-27T00:00:00.000ZRomanian National Study on the Epidemiology of Inflammatory Bowel Diseaseshttps://www.pharmaradar360.com/article/clinical-research-trends-of-laser-therapy-for-onychomycosis-in-korea-china-and-j-7ac2c9b76fda70a4Pharma Surgeen2026-06-27T00:00:00.000ZClinical Research Trends of Laser Therapy for Onychomycosis in Korea, China, and Japan, and Its Applicability in Korean Medicine: A Scoping Reviewhttps://www.pharmaradar360.com/article/clinical-research-trends-in-lidocaine-injection-at-acupoints-a-scoping-review-ee10725939281363Pharma Surgeen2026-06-27T00:00:00.000ZClinical Research Trends in Lidocaine Injection at Acupoints: A Scoping Reviewhttps://www.pharmaradar360.com/article/design-synthesis-and-biological-evaluation-of-potent-cognition-improved-compound-8a79ca0d704d94c6Pharma Surgeen2026-06-27T00:00:00.000ZDesign, Synthesis, and Biological Evaluation of Potent Cognition-Improved Compounds Targeting AMPA Receptor Based on CX717https://www.pharmaradar360.com/article/an-improved-brain-penetrating-nanoformulation-of-the-vipr2-antagonist-peptide-ks-db52ea4f755326c3Pharma Surgeen2026-06-27T00:00:00.000ZAn Improved Brain-Penetrating Nanoformulation of the VIPR2 Antagonist Peptide KS-133 for Treating Cognitive Impairment in Schizophreniahttps://www.pharmaradar360.com/article/approach-to-personalizing-the-treatment-of-osteoporosis-ac83e69b76f0b124Pharma Surgeen2026-06-27T00:00:00.000ZApproach to Personalizing the Treatment of Osteoporosishttps://www.pharmaradar360.com/article/clinical-outcomes-of-capsular-repair-versus-non-repair-after-hip-arthroscopy-for-a467b39792de6737Pharma Surgeen2026-06-27T00:00:00.000ZClinical outcomes of capsular repair versus non-repair after hip arthroscopy for femoroacetabular impingement: a meta-analysishttps://www.pharmaradar360.com/article/investigating-the-effect-of-intermittent-fasting-time-restricted-eating-with-and-2fbc59c1fec62889Pharma Surgeen2026-06-27T00:00:00.000ZInvestigating the effect of intermittent fasting (time-restricted eating) with and without calorie restriction compared to calorie restriction on anthropometric parameters, depression score, and metabolic factors in patients with major depression disorder and obesity: a study protocol for a randomizhttps://www.pharmaradar360.com/article/multidisciplinary-telemedicine-intervention-for-icu-recovery-the-teleport-feasib-0fea1b9c346de16aPharma Surgeen2026-06-27T00:00:00.000ZMultidisciplinary telemedicine intervention for ICU recovery: the TelePORT feasibility randomized trialhttps://www.pharmaradar360.com/article/epigenetic-safety-of-in-vitro-maturation-in-pcos-genome-wide-dna-methylation-pro-34f393033c3513d3Pharma Surgeen2026-06-27T00:00:00.000ZEpigenetic safety of in vitro maturation in PCOS: genome-wide DNA methylation profiling of cord blood from a randomized controlled trialhttps://www.pharmaradar360.com/article/integrated-analysis-of-gut-microbiota-serum-metabolomics-and-proteomics-reveals-ed3a2176378e6788Pharma Surgeen2026-06-27T00:00:00.000ZIntegrated analysis of gut microbiota, serum metabolomics, and proteomics reveals novel associations with clinical symptoms in patients with cerebral infarctionhttps://www.pharmaradar360.com/article/synergistic-cardioprotection-of-colchicine-and-hyperbaric-oxygen-therapy-in-a-ra-377fc1f80300d6b7Pharma Surgeen2026-06-27T00:00:00.000ZSynergistic Cardioprotection of Colchicine and Hyperbaric Oxygen Therapy in a Rat Model of Remote Ischemia‐Reperfusion Injuryhttps://www.pharmaradar360.com/article/a-novel-device-to-improve-the-tolerability-of-intranasal-corticosteroid-sprays-f-e9eb0fb571453af3Pharma Surgeen2026-06-27T00:00:00.000ZA Novel Device to Improve the Tolerability of Intranasal Corticosteroid Sprays for Allergic Rhinitis and Postoperative Chronic Rhinosinusitis: A Crossover Trialhttps://www.pharmaradar360.com/article/modulation-of-respiratory-diseases-by-the-endocannabinoid-system-a-therapeutic-p-6870a9d8b8234ab0Pharma Surgeen2026-06-27T00:00:00.000ZModulation of Respiratory Diseases by the Endocannabinoid System: A Therapeutic Perspectivehttps://www.pharmaradar360.com/article/feasibility-and-process-evaluation-of-cardiac-brief-intervention-cabin-in-patien-520ff6325fd07b07Pharma Surgeen2026-06-27T00:00:00.000ZFeasibility and Process Evaluation of CArdiac Brief INtervention (CABIN) in Patients with ST-Elevation Myocardial Infarction: A Mixed-Method, Pilot Randomised Controlled Trial.https://www.pharmaradar360.com/article/case-series-on-the-efficacy-of-daratumumab-in-treating-patients-with-anti-interf-8f14c2797d2a2d7ePharma Surgeen2026-06-27T00:00:00.000ZCase Series on the Efficacy of Daratumumab in Treating Patients with Anti-Interferon-Gamma Autoantibodieshttps://www.pharmaradar360.com/article/a-second-case-of-recessive-mosaicism-in-i-abca12-i-causing-a-congenital-unilater-53752a1fcce64379Pharma Surgeen2026-06-27T00:00:00.000ZA second case of recessive mosaicism in <i>ABCA12</i> causing a congenital unilateral epidermal nevushttps://www.pharmaradar360.com/article/using-nal-nl3-in-clinical-practice-a-modular-nal-fitting-system-for-real-world-l-9f0e6bd53e8247e5Pharma Surgeen2026-06-27T00:00:00.000ZUsing NAL-NL3 in clinical practice: a modular NAL fitting system for real-world listening needshttps://www.pharmaradar360.com/article/prevalence-predictors-and-clinical-impact-of-vitamin-d-deficiency-on-12-month-ou-3c09360b6bdb5bc7Pharma Surgeen2026-06-27T00:00:00.000ZPrevalence, predictors, and clinical impact of vitamin D deficiency on 12-month outcomes in hip fracture patientshttps://www.pharmaradar360.com/article/multiple-drugs-0959bbed11907609Pharma Surgeen2026-06-27T00:00:00.000ZMultiple drugshttps://www.pharmaradar360.com/article/methadone-b51c16fb2734b6ecPharma Surgeen2026-06-27T00:00:00.000ZMethadonehttps://www.pharmaradar360.com/article/fluoxetine-lamotrigine-9ce06871f2cf2c17Pharma Surgeen2026-06-27T00:00:00.000ZFluoxetine/Lamotriginehttps://www.pharmaradar360.com/article/transparent-keratin-nanocomposite-films-incorporating-silver-nanoparticles-and-a-90028a257c9644d4Pharma Surgeen2026-06-27T00:00:00.000ZTransparent keratin nanocomposite films incorporating silver nanoparticles and aloe vera for wound managementhttps://www.pharmaradar360.com/article/optimizing-tourniquet-pressures-in-knee-arthroscopy-an-international-survey-on-c-97f4d62f790853ccPharma Surgeen2026-06-27T00:00:00.000ZOptimizing tourniquet pressures in knee arthroscopy: an international survey on current practice and a double-blind randomized trialhttps://www.pharmaradar360.com/article/pharmacogenomic-characterization-of-a-uric-acid-metabolism-related-signature-ass-f942d473ac21324aPharma Surgeen2026-06-27T00:00:00.000ZPharmacogenomic characterization of a uric acid metabolism-related signature associated with prognosis and drug sensitivity in gastric cancerhttps://www.pharmaradar360.com/article/clinical-pharmacists-in-primary-care-a-real-world-experience-from-sao-paulo-braz-172804bcc1ea7cfePharma Surgeen2026-06-27T00:00:00.000ZClinical Pharmacists in Primary Care: A Real‐World Experience From São Paulo, Brazilhttps://www.pharmaradar360.com/article/price-to-earnings-forward-of-suzhou-fengbei-biotech-stock-co-ltd-class-a-sse-603-ec5fc02873ee8949Pharma Surgeen2026-06-26T23:59:52.000ZPrice to earnings forward of Suzhou Fengbei Biotech Stock Co., Ltd. Class A – SSE:603334https://www.pharmaradar360.com/article/ema-amgen-vifor-inflammatory-drug-s-benefits-no-longer-outweigh-risks-80766860202ba693Pharma Surgeen2026-06-26T23:43:22.000ZEMA: Amgen, Vifor Inflammatory Drug’s Benefits No Longer Outweigh Riskshttps://www.pharmaradar360.com/article/this-biotech-etf-has-almost-doubled-in-13-months-money-is-flowing-in-barrons-com-6995c9ff64865e07Pharma Surgeen2026-06-26T23:21:39.000ZThis Biotech ETF Has Almost Doubled in 13 Months. Money Is Flowing In. -- Barrons.comhttps://www.pharmaradar360.com/article/pioneering-projects-to-transform-obesity-care-backed-by-85-million-from-governme-0e7a0d3c28749fdbPharma Surgeen2026-06-26T23:01:04.000ZPioneering projects to transform obesity care, backed by £85 million from government and industryhttps://www.pharmaradar360.com/article/medpace-medp-has-a-backlog-and-execution-engine-bigger-than-a-biotech-funding-sc-b4901212b3a8b375Pharma Surgeen2026-06-26T22:39:25.000ZMedpace (MEDP) Has a Backlog-and-Execution Engine Bigger Than a Biotech-Funding Scarehttps://www.pharmaradar360.com/article/price-to-earnings-forward-of-sunhawk-vision-biotech-inc-tpex-7759-adf6cf8c0a4b9eefPharma Surgeen2026-06-26T22:21:52.000ZPrice to earnings forward of Sunhawk Vision Biotech, Inc. – TPEX:7759https://www.pharmaradar360.com/article/lantheus-stock-falls-after-fda-rejects-drug-application-3226385a0511d32fPharma Surgeen2026-06-26T21:30:12.000ZLantheus stock falls after FDA rejects drug applicationhttps://www.pharmaradar360.com/article/matinas-biopharma-receives-notice-of-non-compliance-with-nyse-american-continued-5233053c00e4101fPharma Surgeen2026-06-26T21:15:00.000ZMatinas BioPharma Receives Notice of Non-Compliance with NYSE American Continued Listing Standards and Acceptance of Plan to Regain Compliancehttps://www.pharmaradar360.com/article/west-pharmaceutical-services-inc-stock-outperforms-competitors-on-strong-trading-3f486c113376e67aPharma Surgeen2026-06-26T21:02:00.000ZWest Pharmaceutical Services Inc. stock outperforms competitors on strong trading dayhttps://www.pharmaradar360.com/article/fda-will-reportedly-conclude-abortion-pill-safety-review-by-september-794bb91f5c6a106dPharma Surgeen2026-06-26T21:01:08.000ZFDA Will Reportedly Conclude Abortion Pill Safety Review by Septemberhttps://www.pharmaradar360.com/article/universe-pharmaceuticals-inc-announces-strategic-acquisition-to-expand-pharmaceu-73968fa9437dd07cPharma Surgeen2026-06-26T20:58:14.000ZUniverse Pharmaceuticals Inc Announces Strategic Acquisition To Expand Pharmaceutical Patent Portfoliohttps://www.pharmaradar360.com/article/skyrizi-risankizumab-rzaa-now-fda-approved-for-pediatric-use-in-psoriatic-diseas-3181bcc3d02f16abPharma Surgeen2026-06-26T20:50:00.000ZSKYRIZI® (risankizumab-rzaa) Now FDA Approved for Pediatric Use in Psoriatic Diseasehttps://www.pharmaradar360.com/article/swiss-pharma-at-risk-of-us-trade-investigation-industry-body-says-845e46620aff05f9Pharma Surgeen2026-06-26T20:41:16.000ZSwiss pharma at risk of US trade investigation, industry body sayshttps://www.pharmaradar360.com/article/swiss-pharmaceutical-industry-faces-potential-us-trade-investigation-68563507026fcb7aPharma Surgeen2026-06-26T20:15:23.000ZSwiss pharmaceutical industry faces potential US trade investigationhttps://www.pharmaradar360.com/article/monopar-presents-new-analyses-of-phase-3-focus-data-at-ean-2026-showing-greater-c896051b7b879963Pharma Surgeen2026-06-26T20:11:28.000ZMonopar Presents New Analyses of Phase 3 FoCus Data at EAN 2026 Showing Greater Neurologic and Global Clinical Benefit with ALXN1840 Versus Standard of Care in Wilson Diseasehttps://www.pharmaradar360.com/article/alxn1840-phase-3-data-back-nda-plan-for-wilson-disease-monopar-nasdaq-mnpr-c60111e02ac821f7Pharma Surgeen2026-06-26T20:07:07.000ZALXN1840 Phase 3 data back NDA plan for Wilson disease, Monopar (NASDAQ: MNPR)https://www.pharmaradar360.com/article/monopar-s-wilson-disease-drug-shows-stronger-neurologic-gains-in-phase-3-a3d3cd8a027d1771Pharma Surgeen2026-06-26T20:05:00.000ZMonopar’s Wilson disease drug shows stronger neurologic gains in Phase 3https://www.pharmaradar360.com/article/universe-pharmaceuticals-bets-10-8m-on-five-china-patents-6f4b7dfddae11fadPharma Surgeen2026-06-26T20:05:00.000ZUniverse Pharmaceuticals bets $10.8M on five China patentshttps://www.pharmaradar360.com/article/universe-pharmaceuticals-inc-announces-strategic-acquisition-to-expand-pharmaceu-9437bf440975940aPharma Surgeen2026-06-26T20:05:00.000ZUniverse Pharmaceuticals INC Announces Strategic Acquisition to Expand Pharmaceutical Patent Portfoliohttps://www.pharmaradar360.com/article/this-biotech-etf-has-almost-doubled-in-13-months-money-is-flowing-in-256d2eb032ca56adPharma Surgeen2026-06-26T19:38:00.000ZThis Biotech ETF Has Almost Doubled in 13 Months. Money Is Flowing In.https://www.pharmaradar360.com/article/who-issues-guideline-to-curb-environmental-waste-in-pharmaceutical-manufacturing-bd4d943fc9323b37Pharma Surgeen2026-06-26T19:32:00.000ZWHO issues guideline to curb environmental waste in pharmaceutical manufacturinghttps://www.pharmaradar360.com/article/why-flexibility-is-the-secret-to-modern-biotech-deals-523bb04d8e3ca6c9Pharma Surgeen2026-06-26T18:58:16.000ZWhy Flexibility is the Secret to Modern Biotech Dealshttps://www.pharmaradar360.com/article/maharashtra-fda-shuts-jj-mahanagar-blood-bank-over-safety-violations-7a3ba6da597d8f70Pharma Surgeen2026-06-26T18:49:00.000ZMaharashtra FDA Shuts JJ Mahanagar Blood Bank Over Safety Violationshttps://www.pharmaradar360.com/article/report-lawmakers-say-fda-safety-review-of-abortion-pill-could-be-complete-by-sep-5f24edb388dc17bdPharma Surgeen2026-06-26T18:37:52.000ZReport: Lawmakers Say FDA Safety Review of Abortion Pill Could Be Complete by Septemberhttps://www.pharmaradar360.com/article/the-critical-medicines-act-s-impact-on-pharmaceutical-manufacturing-and-supply-r-42fbfb7c2db0021ePharma Surgeen2026-06-26T18:22:00.000ZThe Critical Medicines Act’s Impact on Pharmaceutical Manufacturing and Supply Resilience in Europehttps://www.pharmaradar360.com/article/free-workshop-measuring-and-characterising-pharma-b5e3e933679dd194Pharma Surgeen2026-06-26T17:46:01.000ZFree Workshop – Measuring and Characterising Pharmahttps://www.pharmaradar360.com/article/anmat-recibio-a-las-autoridades-regulatorias-nacionales-de-referencia-de-las-ame-d62ef488163afb06Pharma Surgeen2026-06-26T16:58:57.000ZANMAT recibió a las Autoridades Regulatorias Nacionales de Referencia de las Américashttps://www.pharmaradar360.com/article/swiss-pharma-at-risk-of-us-trade-investigation-industry-body-says-36be1e776cb1ef04Pharma Surgeen2026-06-26T16:57:05.000ZSwiss pharma at risk of US trade investigation, industry body sayshttps://www.pharmaradar360.com/article/pharmaceutical-technology-1d938edb8cb59679Pharma Surgeen2026-06-26T16:53:05.000ZPharmaceutical Technologyhttps://www.pharmaradar360.com/article/at-bio-tension-over-china-biotech-deal-regulation-looms-799efe1ec960b2cePharma Surgeen2026-06-26T16:03:46.000ZAt BIO, tension over China biotech deal regulation loomshttps://www.pharmaradar360.com/article/exg-7001-60b08321676c056fPharma Surgeen2026-06-26T16:00:00.000ZEXG-7001のオプション契約締結のお知らせhttps://www.pharmaradar360.com/article/is-viking-therapeutics-poised-to-disrupt-the-weight-loss-market-afb5e819ae6f724ePharma Surgeen2026-06-26T15:38:17.000ZIs Viking Therapeutics Poised to Disrupt the Weight-Loss Markethttps://www.pharmaradar360.com/article/ubs-raises-incyte-stock-price-target-to-113-on-biotech-recovery-fcf433cc718ef2fbPharma Surgeen2026-06-26T15:32:59.000ZUBS raises Incyte stock price target to $113 on biotech recoveryhttps://www.pharmaradar360.com/article/thermo-fisher-s-kane-says-ai-is-reshaping-how-cdmos-add-value-ff3d81f8099e425ePharma Surgeen2026-06-26T15:29:10.000ZThermo Fisher's Kane Says AI Is Reshaping How CDMOs Add Valuehttps://www.pharmaradar360.com/article/adragos-pharma-kawagoe-towa-pharmaceutical-ink-strategic-supply-pact-cc4aaea4868ebf4bPharma Surgeen2026-06-26T15:27:39.000ZAdragos Pharma Kawagoe, Towa Pharmaceutical Ink Strategic Supply Pacthttps://www.pharmaradar360.com/article/china-biotech-services-says-bgi-songhe-advances-rmb30-million-loan-to-pengbo-hai-9d6d59f536a82305Pharma Surgeen2026-06-26T15:25:48.000ZChina Biotech Services Says BGI Songhe Advances RMB30 Million Loan To Pengbo (Hainan)https://www.pharmaradar360.com/article/stanowisko-do-projektu-ustawy-o-zmianie-ustawy-o-refundacji-lekow-srodkow-spozyw-fe8e5deac4e53f12Pharma Surgeen2026-06-26T15:25:19.000ZStanowisko do projektu ustawy o zmianie ustawy o refundacji leków, środków spożywczych specjalnego przeznaczenia żywieniowego oraz wyrobów medycznych oraz niektórych innych ustawhttps://www.pharmaradar360.com/article/cold-chain-packaging-market-to-reach-93-1-billion-by-2033-amid-pharmaceutical-an-5bb80e6a19a0b259Pharma Surgeen2026-06-26T15:22:30.000ZCold Chain Packaging Market to Reach $93.1 Billion by 2033 Amid Pharmaceutical and E-commerce Pressureshttps://www.pharmaradar360.com/article/exciting-clinical-trial-results-for-new-endometriosis-scan-6596c4417307b5c0Pharma Surgeen2026-06-26T15:15:38.000Z'Exciting' Clinical Trial Results For New Endometriosis Scanhttps://www.pharmaradar360.com/article/a-breakthrough-designated-depression-drug-is-86-through-its-phase-3-with-topline-d55ccf0549af2c24Pharma Surgeen2026-06-26T15:07:21.000ZA Breakthrough-Designated Depression Drug Is 86% Through Its Phase 3, With Topline Data Due This Yearhttps://www.pharmaradar360.com/article/definium-releases-lsd-for-depression-phase-3-results-and-colorado-activists-figh-9f86436c3c791addPharma Surgeen2026-06-26T15:02:59.000ZDefinium releases LSD for depression Phase 3 results and Colorado activists fight recent bill’s amendments to sharing psychedelicshttps://www.pharmaradar360.com/article/anivive-lifesciences-announces-fda-approval-of-laverdia-oral-treatment-for-canin-bed2fb3df796bd4fPharma Surgeen2026-06-26T15:01:39.000ZAnivive Lifesciences Announces FDA Approval of Laverdia Oral Treatment for Canine Lymphomahttps://www.pharmaradar360.com/article/european-biotechs-developing-next-generation-cell-and-gene-therapy-manufacturing-c2fae5acd50fdf34Pharma Surgeen2026-06-26T15:00:00.000ZEuropean Biotechs Developing Next-Generation Cell and Gene Therapy Manufacturing Technologieshttps://www.pharmaradar360.com/article/geodis-thermal-covers-mark-step-toward-sustainable-pharma-airfreight-packaging-a547fef357437168Pharma Surgeen2026-06-26T14:53:36.000ZGEODIS Thermal Covers Mark Step Toward Sustainable Pharma Airfreight Packaginghttps://www.pharmaradar360.com/article/fermenta-biotech-limited-ranked-7th-nationwide-in-india-s-great-mid-size-workpla-2ebc48c37d6d1d67Pharma Surgeen2026-06-26T14:43:15.000ZFermenta Biotech Limited Ranked 7th Nationwide in India’s Great Mid-size WorkplacesTM 2026https://www.pharmaradar360.com/article/epicrispr-gene-silencer-is-1st-drug-to-boost-muscle-in-form-of-muscular-dystroph-7ce4c6f77b73ca05Pharma Surgeen2026-06-26T14:40:19.000ZEpicrispr gene silencer is 1st drug to boost muscle in form of muscular dystrophy, biotech sayshttps://www.pharmaradar360.com/article/weekly-buzz-ions-mrk-get-fda-approvals-achv-gets-crl-adct-cuts-jobs-tech-acquire-ead4c3fefcd70030Pharma Surgeen2026-06-26T14:33:00.000ZWeekly Buzz: IONS, MRK Get FDA Approvals; ACHV Gets CRL; ADCT Cuts Jobs; TECH Acquiredhttps://www.pharmaradar360.com/article/what-is-the-latest-on-capricor-therapeutics-deramiocel-and-its-fda-journey-0d25ded03b9c208ePharma Surgeen2026-06-26T14:19:02.000ZWhat is the latest on Capricor Therapeutics' Deramiocel and its FDA journeyhttps://www.pharmaradar360.com/article/ukhsa-extends-red-heat-health-alerts-across-england-3ab1f8a5ec9bfc1dPharma Surgeen2026-06-26T14:17:52.000ZUKHSA extends red heat-health alerts across Englandhttps://www.pharmaradar360.com/article/what-s-fueling-olema-pharmaceuticals-explosive-242-stock-surge-17cf652733ce84a6Pharma Surgeen2026-06-26T14:17:08.000ZWhat's Fueling Olema Pharmaceuticals' Explosive 242% Stock Surgehttps://www.pharmaradar360.com/article/register-medical-devices-to-place-on-the-market-931aab8eba5ff651Pharma Surgeen2026-06-26T14:03:03.000ZRegister medical devices to place on the markethttps://www.pharmaradar360.com/article/biogen-ends-apellis-research-programs-cuts-small-number-of-roles-after-5-6b-buyo-a14cdd3f8a43ea73Pharma Surgeen2026-06-26T13:56:36.000ZBiogen ends Apellis research programs, cuts ‘small number’ of roles after $5.6B buyouthttps://www.pharmaradar360.com/article/bio-2026-making-biotech-ipos-great-again-and-the-forgotten-pharma-antitrust-revi-e593f42e9daba114Pharma Surgeen2026-06-26T13:51:22.000ZBIO 2026: Making biotech IPOs great again and the forgotten pharma antitrust reviewhttps://www.pharmaradar360.com/article/price-to-book-forward-of-sunhawk-vision-biotech-inc-tpex-7759-3d9ee68754f503ccPharma Surgeen2026-06-26T13:44:14.000ZPrice to book forward of Sunhawk Vision Biotech, Inc. – TPEX:7759https://www.pharmaradar360.com/article/embryo-editing-advances-reignite-ethical-debates-09ff37118eb1b533Pharma Surgeen2026-06-26T13:43:09.000ZEmbryo editing advances reignite ethical debateshttps://www.pharmaradar360.com/article/pharmaceutical-market-europe-june-2026-d84b311e3cdc4fe0Pharma Surgeen2026-06-26T13:42:16.000ZPharmaceutical Market Europe – June 2026https://www.pharmaradar360.com/article/what-s-driving-rallybio-s-recent-surge-and-investor-interest-68f3b26bdcc03f01Pharma Surgeen2026-06-26T13:33:08.000ZWhat's Driving Rallybio's Recent Surge and Investor Interesthttps://www.pharmaradar360.com/article/a-breakthrough-designated-depression-drug-is-86-through-its-phase-3-with-topline-46655b8d8f56d95bPharma Surgeen2026-06-26T13:30:00.000ZA Breakthrough-Designated Depression Drug Is 86% Through Its Phase 3, With Topline Data Due This Yearhttps://www.pharmaradar360.com/article/has-ocugen-s-recent-convertible-notes-offering-stabilized-its-financial-future-24b60403ee69b13dPharma Surgeen2026-06-26T13:29:29.000ZHas Ocugen's Recent Convertible Notes Offering Stabilized Its Financial Futurehttps://www.pharmaradar360.com/article/the-deal-before-the-deal-3b0eab5c7eeeaf77Pharma Surgeen2026-06-26T13:20:55.000ZThe deal before the dealhttps://www.pharmaradar360.com/article/a-dose-of-disruption-read-the-full-investigative-series-on-empower-711ba25d4b514405Pharma Surgeen2026-06-26T13:18:00.000ZA Dose of Disruption: Read the full investigative series on Empowerhttps://www.pharmaradar360.com/article/enterprise-value-to-ebitda-forward-of-rtw-biotech-opportunities-ltd-usd-fwb-0bm-eef44425562356c9Pharma Surgeen2026-06-26T13:14:48.000ZEnterprise value to EBITDA forward of RTW Biotech Opportunities Ltd USD – FWB:0BMhttps://www.pharmaradar360.com/article/how-china-turned-us-trade-compliance-into-a-supply-chain-risk-91493386362eb16aPharma Surgeen2026-06-26T13:13:32.000ZHow China Turned US Trade Compliance Into a Supply Chain Riskhttps://www.pharmaradar360.com/article/enterprise-value-to-revenue-forward-of-grand-pharmaceutical-group-limited-hkex-5-9e7a26a761bff9c6Pharma Surgeen2026-06-26T13:10:38.000ZEnterprise value to revenue forward of Grand Pharmaceutical Group Limited – HKEX:512https://www.pharmaradar360.com/article/capricor-to-present-positive-five-year-hope-2-ole-data-and-hope-3-phase-3-result-9eaf760c148df482Pharma Surgeen2026-06-26T13:07:58.000ZCapricor to Present Positive Five-Year HOPE-2 OLE Data and HOPE-3 Phase 3 Results for Deramiocel in Duchenne Muscular Dystrophy at PPMD 2026 Annual Conferencehttps://www.pharmaradar360.com/article/capricor-s-duchenne-drug-shows-5-year-muscle-and-heart-data-at-ppmd-308380394cff1b9aPharma Surgeen2026-06-26T13:05:00.000ZCapricor's Duchenne drug shows 5-year muscle and heart data at PPMDhttps://www.pharmaradar360.com/article/it-s-time-to-act-eu-biotech-to-undergo-major-changes-4606aca6feae95acPharma Surgeen2026-06-26T13:02:05.000Z“It’s time to Act”: EU biotech to undergo major changeshttps://www.pharmaradar360.com/article/moderna-enters-in-vivo-car-t-granting-autoimmune-asset-007-license-to-kill-patho-8c14142fe7c43039Pharma Surgeen2026-06-26T13:00:00.000ZModerna enters in vivo CAR-T, granting autoimmune asset ‘007’ license to kill pathogenic cellshttps://www.pharmaradar360.com/article/star-therapeutics-bleeding-disorder-drug-vga039-gets-full-phase-1-2-data-spotlig-d3ba860818bd1ae8Pharma Surgeen2026-06-26T13:00:00.000ZStar Therapeutics' bleeding-disorder drug VGA039 gets full Phase 1/2 data spotlighthttps://www.pharmaradar360.com/article/don-t-make-ai-smarter-make-it-traceable-3dda76f53f2eefc0Pharma Surgeen2026-06-26T12:58:43.000ZDon’t Make AI Smarter. Make It Traceable.https://www.pharmaradar360.com/article/lupin-s-fda-nod-signals-shakeup-for-a-3-5b-prostate-cancer-drug-market-08fb7e8e8f7083ecPharma Surgeen2026-06-26T12:31:00.000ZLupin's FDA Nod Signals Shakeup for a $3.5B Prostate Cancer Drug Markethttps://www.pharmaradar360.com/article/incorporacion-al-mercosur-sobre-productos-de-limpieza-y-afines-09bd92ac1644d59dPharma Surgeen2026-06-26T12:29:24.000ZIncorporación al Mercosur sobre productos de limpieza y afineshttps://www.pharmaradar360.com/article/anmat-inhibio-las-actividades-productivas-de-la-firma-diater-s-r-l-7e0e126d2fc01659Pharma Surgeen2026-06-26T12:23:09.000ZANMAT inhibió las actividades productivas de la firma DIATER S.R.L.https://www.pharmaradar360.com/article/remifentanil-hydrochloride-for-injection-out-of-specification-assay-impurity-9908a70cfc71811bPharma Surgeen2026-06-26T12:00:00.000ZRemifentanil hydrochloride for injection; Out of specification (Assay & Impurity)https://www.pharmaradar360.com/article/turbo-69-54506e9db44a827fPharma Surgeen2026-06-26T11:55:42.000ZTURBO 69 (ΣΤΑΓΟΝΕΣ) / (ΣΙΛΔΕΝΑΦΙΛΗ)https://www.pharmaradar360.com/article/vericel-corp-nasdaq-vcel-a-classic-affordable-growth-stock-in-biotech-362d3e9dd2d3a02bPharma Surgeen2026-06-26T11:50:35.000ZVericel Corp (NASDAQ:VCEL): A Classic Affordable Growth Stock in Biotechhttps://www.pharmaradar360.com/article/group-files-brief-urging-fda-s-reinstatement-of-abortion-pill-restriction-2fb78cd02a61d657Pharma Surgeen2026-06-26T11:50:00.000ZGroup files brief urging FDA's reinstatement of abortion pill restrictionhttps://www.pharmaradar360.com/article/241105viy-10-2027-ref-pga30f0126-rt-med-75cm-usp-3-0-ep-metric-1-2-26-6912ac734b17d5fcPharma Surgeen2026-06-26T11:43:56.000ZΟΡΘΗ-Ανάκληση της παρτίδας 241105VIY, ημ λήξης: 10/2027, (REF: PGA30F0126), του ιατροτεχνολογικού προϊόντος ΧΕΙΡΟΥΡΓΙΚΑ ΡΑΜΜΑΤΑ RT MED Πολύκλωνο Συνθετικό Απορροφήσιμο Πλεκτό Ράμμα – Βιολετί, 75CM, USP 3/0, EP METRIC 1/2 κύκλου, στρογγυλή βελόνη 26 χιλhttps://www.pharmaradar360.com/article/why-is-intellia-therapeutics-ntla-a-battleground-stock-with-38-short-interest-ac440ef295d82fe1Pharma Surgeen2026-06-26T11:40:27.000ZWhy is Intellia Therapeutics (NTLA) a Battleground Stock with 38% Short Interesthttps://www.pharmaradar360.com/article/imcd-opens-us-dietary-supplements-technical-hub-to-accelerate-innovation-ca77610be432afa4Pharma Surgeen2026-06-26T11:35:25.000ZIMCD opens US dietary supplements technical hub to accelerate innovationhttps://www.pharmaradar360.com/article/240592-perfume-mall-women-s-eau-de-perfume-1aa1c0d0246f391aPharma Surgeen2026-06-26T11:34:43.000ZΑνάκληση της παρτίδας 240592, του καλλυντικού προϊόντος Perfume Mall WOMEN’S EAU DE PERFUMEhttps://www.pharmaradar360.com/article/vivani-medical-announces-appointment-of-august-j-moretti-to-board-of-directors-a-2d214fdf66cad5b4Pharma Surgeen2026-06-26T11:30:00.000ZVivani Medical Announces Appointment of August J. Moretti to Board of Directors and Retirement of Dr. Dean Bakerhttps://www.pharmaradar360.com/article/q-a-why-pharma-deal-volume-is-down-but-value-is-up-0abfb6604ec9d586Pharma Surgeen2026-06-26T11:29:06.000ZQ&A: Why Pharma Deal Volume Is Down but Value Is Uphttps://www.pharmaradar360.com/article/21393a07c-tesori-d-oriente-fior-di-loto-aromatic-perfume-100ml-bb602a3a10c8776cPharma Surgeen2026-06-26T11:26:48.000ZΑνάκληση της παρτίδας 21393A07C, του καλλυντικού προϊόντος Tesori d’ Oriente Fior di Loto Aromatic Perfume 100mlhttps://www.pharmaradar360.com/article/manushield-cleaner-d4dab93d8cc47949Pharma Surgeen2026-06-26T11:22:29.000ZΑνάκληση παρτίδας του προϊόντος MANUSHIELD CLEANERhttps://www.pharmaradar360.com/article/enterprise-value-to-ebitda-forward-of-purple-biotech-ltd-nasdaq-ppbt-54c36a7050cbbfa0Pharma Surgeen2026-06-26T11:22:20.000ZEnterprise value to EBITDA forward of Purple Biotech Ltd. – NASDAQ:PPBThttps://www.pharmaradar360.com/article/now-zinc-gluconate-50mg-250-tabs-93c4f17b9d93a07bPharma Surgeen2026-06-26T11:18:26.000ZΑπαγόρευση διάθεσης και διακίνησης του συμπληρώματος διατροφής NOW ZINC GLUCONATE 50MG, 250 TABShttps://www.pharmaradar360.com/article/lilly-s-jaypirca-pirtobrutinib-recommended-by-chmp-for-approval-in-the-european-ed46d54504400b6aPharma Surgeen2026-06-26T11:16:00.000ZLilly's Jaypirca (pirtobrutinib) recommended by CHMP for approval in the European Union for adults with chronic lymphocytic leukemia (CLL) across all lines of therapyhttps://www.pharmaradar360.com/article/axsome-starts-phase-3-trial-of-solriamfetol-for-adhd-in-adolescents-aiming-to-im-b350e465b798b6dcPharma Surgeen2026-06-26T11:15:21.000ZAxsome starts Phase 3 trial of solriamfetol for ADHD in adolescents, aiming to improve treatment options.https://www.pharmaradar360.com/article/hiro-lab-tongkat-ali-400mg-hiro-lab-turkesterone-600mg-1c8da9c4681bb79cPharma Surgeen2026-06-26T11:11:38.000ZΑπαγόρευση διάθεσης και διακίνησης των συμπληρωμάτων διατροφής Hiro.Lab Tongkat Ali 400MG, Hiro.Lab Turkesterone 600mghttps://www.pharmaradar360.com/article/compound-pharmacies-are-outrunning-regulations-experts-want-tougher-oversight-a4d199120cadaea9Pharma Surgeen2026-06-26T11:08:31.000ZCompound pharmacies are outrunning regulations. Experts want tougher oversight.https://www.pharmaradar360.com/article/key-takeaways-from-a-chronicle-examination-of-empower-pharmacy-3f7bc426d7b1091cPharma Surgeen2026-06-26T11:08:31.000ZKey takeaways from a Chronicle examination of Empower Pharmacyhttps://www.pharmaradar360.com/article/here-s-how-we-examined-houston-based-empower-pharmacy-s-expansion-2c4a74ba264d1b69Pharma Surgeen2026-06-26T11:08:31.000ZHere's how we examined Houston-based Empower Pharmacy's expansionhttps://www.pharmaradar360.com/article/axsome-therapeutics-initiates-focus-3-phase-3-trial-of-solriamfetol-in-adolescen-7e4e528b4f776335Pharma Surgeen2026-06-26T11:05:29.000ZAxsome Therapeutics Initiates FOCUS-3 Phase 3 Trial of Solriamfetol in Adolescents with Attention Deficit Hyperactivity Disorder (ADHD)https://www.pharmaradar360.com/article/omakase-world-market-is-the-bay-area-s-most-surprising-new-food-hall-31b68bc365e513a5Pharma Surgeen2026-06-26T11:03:07.000ZOmakase World Market is the Bay Area's most surprising new food hallhttps://www.pharmaradar360.com/article/fda-to-discuss-easing-restrictions-on-peptides-despite-safety-concerns-ba8fa9e1bcd94824Pharma Surgeen2026-06-26T11:02:00.000ZFDA to discuss easing restrictions on peptides despite safety concernshttps://www.pharmaradar360.com/article/rx-rundown-merck-kgaa-abbvie-sangamo-therapeutics-and-more-46b1895be6f00be2Pharma Surgeen2026-06-26T11:01:36.000ZRx Rundown: Merck KGaA, AbbVie, Sangamo Therapeutics and morehttps://www.pharmaradar360.com/article/fda-weighs-legalizing-gray-market-peptides-amid-escalating-safety-concerns-05eb29b1ca1d6519Pharma Surgeen2026-06-26T11:00:16.000ZFDA Weighs Legalizing Gray-Market Peptides Amid Escalating Safety Concernshttps://www.pharmaradar360.com/article/axsome-starts-468-patient-adhd-trial-for-teens-4d97a5f680596e79Pharma Surgeen2026-06-26T11:00:00.000ZAxsome starts 468-patient ADHD trial for teenshttps://www.pharmaradar360.com/article/aethlon-medical-tracks-ebola-outbreak-readies-hemopurifier-talks-9f3bb3559a64882bPharma Surgeen2026-06-26T11:00:00.000ZAethlon Medical tracks Ebola outbreak, readies Hemopurifier talkshttps://www.pharmaradar360.com/article/from-vaccines-to-therapeutics-how-biotech-is-addressing-the-ebola-outbreak-a75589f8f3267be3Pharma Surgeen2026-06-26T11:00:00.000ZFrom Vaccines to Therapeutics; How Biotech Is Addressing the Ebola Outbreakhttps://www.pharmaradar360.com/article/mediterrania-portfolio-company-laprophan-acquires-rivopharm-7c4b9231a6f0ce65Pharma Surgeen2026-06-26T10:40:17.000ZMediterrania portfolio company Laprophan acquires Rivopharmhttps://www.pharmaradar360.com/article/tryngolza-charts-blockbuster-course-after-fda-s-hypertriglyceridemia-approval-2d918ec660c14cfePharma Surgeen2026-06-26T10:33:39.000ZTryngolza charts blockbuster course after FDA’s hypertriglyceridemia approvalhttps://www.pharmaradar360.com/article/quarterly-epidemiological-commentary-mandatory-mrsa-mssa-and-gram-negative-bacte-21e80aa813c48412Pharma Surgeen2026-06-26T10:32:27.000ZQuarterly Epidemiological Commentary: mandatory MRSA, MSSA and Gram-negative bacteraemia and Clostridioides difficile infection, data up to January to March 2026https://www.pharmaradar360.com/article/mexiletine-pr-564e51f22fbdac57Pharma Surgeen2026-06-26T10:21:39.000ZMexiletine PRhttps://www.pharmaradar360.com/article/hepatitis-b-antenatal-screening-and-selective-neonatal-immunisation-pathway-d8b93786f729959cPharma Surgeen2026-06-26T10:11:56.000ZHepatitis B: antenatal screening and selective neonatal immunisation pathwayhttps://www.pharmaradar360.com/article/decision-orphan-registered-medicinal-products-20a088b198fbcb50Pharma Surgeen2026-06-26T10:06:50.000ZDecision: Orphan registered medicinal productshttps://www.pharmaradar360.com/article/uk-malaria-expert-advisory-group-ukmeag-6b3d8243950c8703Pharma Surgeen2026-06-26T10:02:56.000ZUK Malaria Expert Advisory Group (UKMEAG)https://www.pharmaradar360.com/article/kazde-1-euro-zainwestowane-w-nowe-leki-przynosi-europie-5-67-euro-zwrotu-a686d6d0c71a0289Pharma Surgeen2026-06-26T09:49:10.000ZKażde 1 euro zainwestowane w nowe leki przynosi Europie 5,67 euro zwrotu.https://www.pharmaradar360.com/article/bio-2026-former-fda-staff-question-agency-s-radical-transparency-approach-15f344ca3097def3Pharma Surgeen2026-06-26T09:47:01.000ZBIO 2026: Former FDA staff question agency’s “radical transparency” approachhttps://www.pharmaradar360.com/article/san-diego-biopharma-begins-first-in-human-dosing-of-obesity-drug-as-phase-3-cata-892ffe88dada61d6Pharma Surgeen2026-06-26T09:45:15.000ZSan Diego Biopharma Begins First-in-Human Dosing of Obesity Drug as Phase 3 Catalysts Approachhttps://www.pharmaradar360.com/article/intrathecal-antibody-test-request-form-ad4dcac995d99f1dPharma Surgeen2026-06-26T09:44:26.000ZIntrathecal antibody test request formhttps://www.pharmaradar360.com/article/enterprise-value-to-ebit-forward-of-consun-pharmaceutical-group-ltd-hkex-1681-10dd56e132a422dbPharma Surgeen2026-06-26T09:44:13.000ZEnterprise value to EBIT forward of Consun Pharmaceutical Group Ltd. – HKEX:1681https://www.pharmaradar360.com/article/polyomavirus-jc-investigation-request-form-e13-5572d7f1731b0921Pharma Surgeen2026-06-26T09:40:57.000ZPolyomavirus JC investigation request form E13https://www.pharmaradar360.com/article/us-biotech-index-hits-record-high-danske-bank-cites-several-drivers-4077e21bef5cc833Pharma Surgeen2026-06-26T09:40:00.000ZUS biotech index hits record high, Danske Bank cites several drivershttps://www.pharmaradar360.com/article/price-to-book-forward-of-dizal-jiangsu-pharmaceutical-co-ltd-class-a-sse-688192-45cb49674c0d409fPharma Surgeen2026-06-26T09:37:52.000ZPrice to book forward of Dizal (Jiangsu) Pharmaceutical Co. Ltd. Class A – SSE:688192https://www.pharmaradar360.com/article/parvovirus-b19-referral-form-8dc7a59f7518c10aPharma Surgeen2026-06-26T09:37:08.000ZParvovirus B19 referral formhttps://www.pharmaradar360.com/article/varicella-zoster-virus-referral-form-87218879c2490674Pharma Surgeen2026-06-26T09:32:34.000ZVaricella zoster virus referral formhttps://www.pharmaradar360.com/article/enterprise-value-to-ebit-forward-of-shandong-xinhua-pharmaceutical-company-limit-5e0bf2c3a3a6cab4Pharma Surgeen2026-06-26T09:31:13.000ZEnterprise value to EBIT forward of Shandong Xinhua Pharmaceutical Company Limited Class H – LSX:A0M4YVhttps://www.pharmaradar360.com/article/hhv-6-and-hhv-7-referral-form-a9e04d646937cbb7Pharma Surgeen2026-06-26T09:26:29.000ZHHV-6 and HHV-7 referral formhttps://www.pharmaradar360.com/article/cnx-and-legacy-set-july-us-relaunch-for-ethyol-ebe5303f1be89f14Pharma Surgeen2026-06-26T09:21:54.000ZCNX and Legacy set July US relaunch for Ethyolhttps://www.pharmaradar360.com/article/2-nationwide-recalls-you-ll-want-to-check-today-871f5c78559871e1Pharma Surgeen2026-06-26T09:15:20.000Z2 nationwide recalls you’ll want to check todayhttps://www.pharmaradar360.com/article/otsuka-posts-positive-phase-iiib-data-for-novel-adhd-therapy-822dbafb438e1266Pharma Surgeen2026-06-26T09:11:51.000ZOtsuka posts positive Phase IIIb data for novel ADHD therapyhttps://www.pharmaradar360.com/article/how-ibio-aims-to-stand-out-in-obesity-by-targeting-both-sides-of-the-equation-fo-0be528ca5f6669fbPharma Surgeen2026-06-26T09:00:14.000ZHow iBio aims to stand out in obesity by targeting ‘both sides of the equation’ for antibody discoveryhttps://www.pharmaradar360.com/article/disponibilite-amelioree-du-zypadhera-poudre-et-solvant-pour-suspension-injectabl-b3a54536fec61316Pharma Surgeen2026-06-26T08:53:52.000ZDisponibilité améliorée du Zypadhera (poudre et solvant pour suspension injectable à libération prolongée) : assouplissement et recommandations adaptées pour les médecins (spécialistes), les pharmaciens (hospitaliers) et les patientshttps://www.pharmaradar360.com/article/debt-to-equity-ratio-of-gin-hwa-biotech-inc-tpex-7806-01f378f4e1b93d46Pharma Surgeen2026-06-26T08:53:50.000ZDebt to equity ratio of Gin Hwa Biotech, Inc. – TPEX:7806https://www.pharmaradar360.com/article/pharmaceutical-technology-fb92345e3e5c13daPharma Surgeen2026-06-26T08:53:38.000ZPharmaceutical Technologyhttps://www.pharmaradar360.com/article/explosion-and-fire-at-pharmaceutical-facility-in-new-york-state-0516ee6382f69c90Pharma Surgeen2026-06-26T08:48:16.000ZExplosion and fire at pharmaceutical facility in New York Statehttps://www.pharmaradar360.com/article/long-term-debt-to-total-assets-ratio-of-gin-hwa-biotech-inc-tpex-7806-c7ca9b20a6acfc5fPharma Surgeen2026-06-26T08:44:04.000ZLong term debt to total assets ratio of Gin Hwa Biotech, Inc. – TPEX:7806https://www.pharmaradar360.com/article/enterprise-value-of-gin-hwa-biotech-inc-tpex-7806-a8afe7c5336ff10fPharma Surgeen2026-06-26T08:41:49.000ZEnterprise value of Gin Hwa Biotech, Inc. – TPEX:7806https://www.pharmaradar360.com/article/debt-to-assets-ratio-of-gin-hwa-biotech-inc-tpex-7806-967f7174ee40d795Pharma Surgeen2026-06-26T08:40:53.000ZDebt to assets ratio of Gin Hwa Biotech, Inc. – TPEX:7806https://www.pharmaradar360.com/article/krystal-biotech-krys-rallies-on-pipeline-optimism-is-the-stock-already-pricey-fee4ba808a83171fPharma Surgeen2026-06-26T08:39:03.000ZKrystal Biotech (KRYS) Rallies On Pipeline Optimism, Is The Stock Already Pricey?https://www.pharmaradar360.com/article/enterprise-value-to-ebit-forward-of-gin-hwa-biotech-inc-tpex-7806-e536e0169386cdbfPharma Surgeen2026-06-26T08:37:48.000ZEnterprise value to EBIT forward of Gin Hwa Biotech, Inc. – TPEX:7806https://www.pharmaradar360.com/article/enterprise-value-to-revenue-forward-of-gin-hwa-biotech-inc-tpex-7806-5282c66628bef04aPharma Surgeen2026-06-26T08:37:06.000ZEnterprise value to revenue forward of Gin Hwa Biotech, Inc. – TPEX:7806https://www.pharmaradar360.com/article/price-to-book-forward-of-pharmagreen-biotech-inc-otc-phbi-877eb5b0e73534adPharma Surgeen2026-06-26T08:37:02.000ZPrice to book forward of Pharmagreen Biotech Inc. – OTC:PHBIhttps://www.pharmaradar360.com/article/enterprise-value-to-ebitda-ratio-of-gin-hwa-biotech-inc-tpex-7806-5cf1854633d84a95Pharma Surgeen2026-06-26T08:36:52.000ZEnterprise value to EBITDA ratio of Gin Hwa Biotech, Inc. – TPEX:7806https://www.pharmaradar360.com/article/operating-margin-of-gin-hwa-biotech-inc-tpex-7806-cfd5502829f86eebPharma Surgeen2026-06-26T08:36:17.000ZOperating margin % of Gin Hwa Biotech, Inc. – TPEX:7806https://www.pharmaradar360.com/article/net-margin-of-gin-hwa-biotech-inc-tpex-7806-64015955cdc56150Pharma Surgeen2026-06-26T08:35:33.000ZNet margin % of Gin Hwa Biotech, Inc. – TPEX:7806https://www.pharmaradar360.com/article/uk-biotech-thalia-therapeutics-raises-3-1-million-and-acquires-sanmirna-therapeu-c97cd65a592b2ee4Pharma Surgeen2026-06-26T08:34:20.000ZUK BioTech Thalia Therapeutics raises €3.1 million and acquires Sanmirna Therapeuticshttps://www.pharmaradar360.com/article/internal-eu-document-biotech-act-has-only-limited-impact-e7327a15d15f6f0fPharma Surgeen2026-06-26T08:31:47.000ZInternal EU document: Biotech Act has only limited impacthttps://www.pharmaradar360.com/article/new-aspe-report-finds-u-s-revenue-fuels-disproportionate-share-of-pharmaceutical-2377f20dbad85fc4Pharma Surgeen2026-06-26T08:31:00.000ZNew ASPE Report Finds U.S. Revenue Fuels Disproportionate Share of Pharmaceutical R&D Incentiveshttps://www.pharmaradar360.com/article/clostridioides-difficile-ribotyping-network-cdrn-report-cd445f04a8fc7f7fPharma Surgeen2026-06-26T08:30:00.000ZClostridioides difficile ribotyping network (CDRN) reporthttps://www.pharmaradar360.com/article/1-2026-811dc4dddb802ca1Pharma Surgeen2026-06-26T08:25:50.000ZΤιμολόγηση Νέων Φαρμακευτικών Προϊόντων_Νέα 1ου Τριμήνου 2026_Ανατιμολόγηση προϊόντων αναφοράς λόγω λήξης της προστασίας δεδομένων τους_Εξέταση αιτημάτων αναπροσαρμογής τιμής μη αποζημιούμενων σκευασμάτωνhttps://www.pharmaradar360.com/article/dhsc-business-appointment-rules-advice-3b5125a476d37863Pharma Surgeen2026-06-26T08:23:33.000ZDHSC: business appointment rules advicehttps://www.pharmaradar360.com/article/dhsc-business-appointment-rules-advice-january-to-march-2026-9c825b6c03b30e94Pharma Surgeen2026-06-26T08:23:31.000ZDHSC: business appointment rules advice, January to March 2026https://www.pharmaradar360.com/article/weekly-all-cause-mortality-surveillance-week-ending-28-june-2026-d61cebbdb2add2dePharma Surgeen2026-06-26T08:13:06.000ZWeekly all-cause mortality surveillance: week ending 28 June 2026https://www.pharmaradar360.com/article/is-viking-therapeutics-stock-a-no-brainer-buy-below-35-a528898970a236d0Pharma Surgeen2026-06-26T08:12:42.000ZIs Viking Therapeutics Stock a No-Brainer Buy Below $35?https://www.pharmaradar360.com/article/women-should-be-valued-and-protected-in-pregnancy-heartbeat-weighs-in-on-abortio-410c1628f6a12456Pharma Surgeen2026-06-26T08:01:54.000Z“Women should be valued and protected in pregnancy” – Heartbeat weighs in on abortion pill casehttps://www.pharmaradar360.com/article/lilly-launches-the-memory-radio-station-across-europe-inviting-the-public-to-vis-a0c91c981e0a2b2ePharma Surgeen2026-06-26T08:00:00.000ZLilly launches “The Memory Radio Station” across Europe, inviting the public to visually reconstruct fading memories through GenAIhttps://www.pharmaradar360.com/article/expired-gear-missing-records-2-mumbai-thane-blood-centres-shut-over-safety-lapse-4c338748db5d7bd7Pharma Surgeen2026-06-26T07:41:03.000ZExpired gear, missing records: 2 Mumbai, Thane blood centres shut over safety lapseshttps://www.pharmaradar360.com/article/proqr-validates-rna-editing-platform-and-raises-59-2m-fb73a6cbf3661ba9Pharma Surgeen2026-06-26T07:37:20.000ZProQR validates RNA editing platform and raises $59.2mhttps://www.pharmaradar360.com/article/assenagon-asset-management-s-a-decreases-stock-holdings-in-teva-pharmaceutical-i-340ad7b850fadc3aPharma Surgeen2026-06-26T07:17:58.000ZAssenagon Asset Management S.A. Decreases Stock Holdings in Teva Pharmaceutical Industries Ltd. $TEVAhttps://www.pharmaradar360.com/article/what-does-briacell-s-latest-offering-mean-for-shareholders-0945e6fa4f984948Pharma Surgeen2026-06-26T06:55:58.000ZWhat Does BriaCell's Latest Offering Mean for Shareholdershttps://www.pharmaradar360.com/article/gcp-breakdown-at-king-s-college-hospital-just-clouded-the-most-promising-parkins-5284224154e6aa79Pharma Surgeen2026-06-26T06:53:06.000ZGCP Breakdown at King’s College Hospital Just Clouded the Most Promising Parkinson’s Trial in Yearshttps://www.pharmaradar360.com/article/unapproved-retatrutide-use-challenges-clinicians-a54228fb90667cfdPharma Surgeen2026-06-26T06:42:33.000ZUnapproved Retatrutide Use Challenges Clinicianshttps://www.pharmaradar360.com/article/enterprise-value-to-revenue-forward-of-teva-pharmaceutical-industries-limited-sp-18729f331f01cd3dPharma Surgeen2026-06-26T06:35:22.000ZEnterprise value to revenue forward of Teva Pharmaceutical Industries Limited Sponsored ADR – FWB:TEVhttps://www.pharmaradar360.com/article/helus-shares-experience-studying-adjunctive-psychedelic-for-major-depressive-dis-4b3d93d40f3cc793Pharma Surgeen2026-06-26T06:31:40.000ZHelus Shares Experience Studying Adjunctive Psychedelic For Major Depressive Disorderhttps://www.pharmaradar360.com/article/rtw-biotech-invests-1-4-million-in-lycia-series-d-financing-3354a90a154b3c54Pharma Surgeen2026-06-26T06:30:00.000ZRTW Biotech Invests $1.4 Million In Lycia Series D Financinghttps://www.pharmaradar360.com/article/3-clinical-stage-biotech-stocks-worth-watching-in-parkinson-s-research-ddf5ae08cf0d24b4Pharma Surgeen2026-06-26T06:22:08.000Z3 Clinical-Stage Biotech Stocks Worth Watching In Parkinson's Researchhttps://www.pharmaradar360.com/article/korea-s-chip-fund-makes-first-biotech-bet-backing-ligachem-with-323-million-719fc6787bbc7329Pharma Surgeen2026-06-26T06:19:52.000ZKorea's chip fund makes first biotech bet, backing LigaChem with $323 millionhttps://www.pharmaradar360.com/article/korea-s-chip-fund-makes-first-biotech-bet-backing-ligachem-with-323-million-202b0cd2cf33f5afPharma Surgeen2026-06-26T05:50:13.000ZKorea's chip fund makes first biotech bet, backing LigaChem with $323 millionhttps://www.pharmaradar360.com/article/first-aid-biotech-act-deal-by-christmas-95157e9e88af4606Pharma Surgeen2026-06-26T05:48:01.000ZFIRST AID: Biotech Act deal by Christmas?https://www.pharmaradar360.com/article/lupin-gets-tentative-us-fda-approval-for-generic-prostate-cancer-drug-9fc4898b6ced2be7Pharma Surgeen2026-06-26T05:29:01.000ZLupin gets tentative US FDA approval for generic prostate cancer drughttps://www.pharmaradar360.com/article/what-does-the-fda-s-priority-review-mean-for-savara-s-molbreevi-1f9a05fd068c4e21Pharma Surgeen2026-06-26T05:24:24.000ZWhat Does the FDA's Priority Review Mean for Savara's MOLBREEVIhttps://www.pharmaradar360.com/article/from-data-to-decisions-how-ipsen-turns-medical-data-into-action-for-patients-ea0233d867d2b2abPharma Surgeen2026-06-26T05:01:55.000ZFrom data to decisions: how Ipsen turns medical data into action for patientshttps://www.pharmaradar360.com/article/why-is-sanofi-s-tolebrutinib-facing-a-regulatory-split-941a9c08b59ee378Pharma Surgeen2026-06-26T04:38:53.000ZWhy is Sanofi's Tolebrutinib Facing a Regulatory Splithttps://www.pharmaradar360.com/article/first-aid-kit-recall-north-american-rescue-issues-correction-for-first-aid-kits-e9b5410d420b548bPharma Surgeen2026-06-26T04:00:00.000ZFirst Aid Kit Recall: North American Rescue Issues Correction for First Aid Kits Containing TRUE METRIX Deviceshttps://www.pharmaradar360.com/article/what-do-moonlake-s-latest-week-40-hs-results-really-mean-for-investors-9f702ce2a4a5c8ffPharma Surgeen2026-06-26T03:14:47.000ZWhat Do MoonLake's Latest Week 40 HS Results Really Mean for Investorshttps://www.pharmaradar360.com/article/how-glp-1-demand-is-reshaping-pharma-manufacturing-strategy-449d3c541f79107aPharma Surgeen2026-06-26T01:58:08.000ZHow GLP-1 Demand Is Reshaping Pharma Manufacturing Strategyhttps://www.pharmaradar360.com/article/what-does-breakthrough-therapy-designation-mean-for-relay-therapeutics-0552e377f4ba3054Pharma Surgeen2026-06-26T01:37:17.000ZWhat Does Breakthrough Therapy Designation Mean for Relay Therapeuticshttps://www.pharmaradar360.com/article/drug-maker-sues-to-halt-implementation-of-arkansas-new-pharmaceutical-distributi-3bc547afe7c747d7Pharma Surgeen2026-06-26T01:30:00.000ZDrug maker sues to halt implementation of Arkansas' new pharmaceutical distribution lawhttps://www.pharmaradar360.com/article/recce-pharmaceuticals-rce-investor-presentation-summary-0037e81161ff9200Pharma Surgeen2026-06-26T01:28:31.000ZRecce Pharmaceuticals (RCE) Investor presentation Summaryhttps://www.pharmaradar360.com/article/recce-raises-a-4m-as-it-advances-anti-infective-trials-and-commercial-licensing-05a6e7bac0e1db4ePharma Surgeen2026-06-26T01:12:16.000ZRecce raises A$4M as it advances anti-infective trials and commercial licensing plans; another $4M to come in SPPhttps://www.pharmaradar360.com/article/hong-kong-biotech-delegation-makes-strong-us-showing-at-bio-2026-50eeed6bead0c6d0Pharma Surgeen2026-06-26T01:10:08.000ZHong Kong biotech delegation makes strong US showing at BIO 2026https://www.pharmaradar360.com/article/dailypharmkorea-239d9f58bc2463c6Pharma Surgeen2026-06-26T00:50:24.000Z데일리팜코리아, 데일리팜 영문뉴스, dailypharmkoreahttps://www.pharmaradar360.com/article/us-fda-declines-to-approve-achieve-life-sciences-smoking-cessation-drug-7f39ea1a8193483fPharma Surgeen2026-06-26T00:41:20.000ZUS FDA declines to approve Achieve Life Sciences' smoking-cessation drughttps://www.pharmaradar360.com/article/gsk-filed-form-6-k-cba2126807971e0bPharma Surgeen2026-06-26T00:00:00.000ZGSK filed Form 6-Khttps://www.pharmaradar360.com/article/santen-obtains-marketing-approval-in-the-philippines-for-stn1012700-ryjusea-0-25-c50cd231bb348a46Pharma Surgeen2026-06-26T00:00:00.000ZSanten Obtains Marketing Approval in the Philippines for STN1012700 (Ryjusea 0.25mg/mL Ophthalmic Solution), an Ophthalmic Solution to Slow the Progression of Myopia — First Approval in Santen’s Asia Business Regionhttps://www.pharmaradar360.com/article/agency-information-collection-activities-proposed-collection-comment-request-pro-1e4392a0904f6fb2Pharma Surgeen2026-06-26T00:00:00.000ZAgency Information Collection Activities: Proposed Collection; Comment Request Proposed Project: Request To Publish the 30-Day Notices in the Federal Register To Solicit Public Comment on Information Collection for the Continued Approval and Updates for the Protection and Advocacy for Individuals Wihttps://www.pharmaradar360.com/article/agency-information-collection-activities-submission-for-office-of-management-and-d412273cbac0868fPharma Surgeen2026-06-26T00:00:00.000ZAgency Information Collection Activities: Submission for Office of Management and Budget Review (OMB); Comment Requesthttps://www.pharmaradar360.com/article/proposed-information-collection-activity-tanf-contingency-fund-application-8e6717d5e53dca83Pharma Surgeen2026-06-26T00:00:00.000ZProposed Information Collection Activity; TANF Contingency Fund Applicationhttps://www.pharmaradar360.com/article/proposed-data-collection-submitted-for-public-comment-and-recommendations-62a3870eb31c6b22Pharma Surgeen2026-06-26T00:00:00.000ZProposed Data Collection Submitted for Public Comment and Recommendationshttps://www.pharmaradar360.com/article/determination-that-prednisolone-tablet-5-milligrams-was-not-withdrawn-from-sale-5cbb9930f4b8110cPharma Surgeen2026-06-26T00:00:00.000ZDetermination That Prednisolone Tablet, 5 Milligrams, Was Not Withdrawn From Sale for Reasons of Safety or Effectivenesshttps://www.pharmaradar360.com/article/agency-forms-undergoing-paperwork-reduction-act-review-0ce06407fb5fbc40Pharma Surgeen2026-06-26T00:00:00.000ZAgency Forms Undergoing Paperwork Reduction Act Reviewhttps://www.pharmaradar360.com/article/determination-that-rectiv-nitroglycerin-ointment-0-4-was-not-withdrawn-from-sale-78aacdef6bdfd448Pharma Surgeen2026-06-26T00:00:00.000ZDetermination That RECTIV (Nitroglycerin) Ointment, 0.4%, Was Not Withdrawn From Sale for Reasons of Safety or Effectivenesshttps://www.pharmaradar360.com/article/unaccompanied-children-program-foundational-rule-sponsor-assessment-update-to-in-79e62fa99dd15119Pharma Surgeen2026-06-26T00:00:00.000ZUnaccompanied Children Program Foundational Rule; Sponsor Assessment Update To Include Proof of Identity, Background Check, Placement, and Income Verification Standardshttps://www.pharmaradar360.com/article/agency-information-collection-activities-submission-for-omb-review-comment-reque-ac6642209c0f46e5Pharma Surgeen2026-06-26T00:00:00.000ZAgency Information Collection Activities: Submission for OMB Review; Comment Requesthttps://www.pharmaradar360.com/article/list-of-bulk-drug-substances-for-which-there-is-a-clinical-need-under-section-50-51dfcd447654846fPharma Surgeen2026-06-26T00:00:00.000ZList of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B of the Federal Food, Drug, and Cosmetic Act; Extension of Comment Periodhttps://www.pharmaradar360.com/article/drugs-for-human-use-drug-efficacy-study-implementation-estrogen-androgen-fixed-c-c14fdf1b589c4f6fPharma Surgeen2026-06-26T00:00:00.000ZDrugs for Human Use; Drug Efficacy Study Implementation: Estrogen-Androgen Fixed-Combination Drug Products; Extension of Effective Date of Final Resolution of Drug Efficacy Study Implementation 7661https://www.pharmaradar360.com/article/medicare-program-cy-2027-changes-to-the-end-stage-renal-disease-esrd-prospective-46be29354f50792dPharma Surgeen2026-06-26T00:00:00.000ZMedicare Program; CY 2027 Changes to the End-Stage Renal Disease (ESRD) Prospective Payment System, Acute Kidney Injury Dialysis (AKI) Payment, and ESRD Quality Incentive Programhttps://www.pharmaradar360.com/article/revocation-of-three-authorizations-of-emergency-use-of-in-vitro-diagnostic-devic-c8b1e6f1317763d8Pharma Surgeen2026-06-26T00:00:00.000ZRevocation of Three Authorizations of Emergency Use of In Vitro Diagnostic Devices for Detection and/or Diagnosis of COVID-19; Availabilityhttps://www.pharmaradar360.com/article/medical-devices-general-hospital-and-personal-use-devices-classification-of-the-deed70298e92f6c8Pharma Surgeen2026-06-26T00:00:00.000ZMedical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep Systemhttps://www.pharmaradar360.com/article/medical-devices-neurological-devices-classification-of-the-external-lower-extrem-e26723df872266e0Pharma Surgeen2026-06-26T00:00:00.000ZMedical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs Syndromehttps://www.pharmaradar360.com/article/medical-devices-general-and-plastic-surgery-devices-classification-of-the-breast-4889dc353305df41Pharma Surgeen2026-06-26T00:00:00.000ZMedical Devices; General and Plastic Surgery Devices; Classification of the Breast Implant Suction Retrieval Systemhttps://www.pharmaradar360.com/article/medical-devices-immunology-and-microbiology-devices-classification-of-the-sars-c-f3473c1857637408Pharma Surgeen2026-06-26T00:00:00.000ZMedical Devices; Immunology and Microbiology Devices; Classification of the SARS-CoV-2 Serology Testhttps://www.pharmaradar360.com/article/medical-devices-neurological-devices-classification-of-the-computerized-behavior-2bc12ac245122e6ePharma Surgeen2026-06-26T00:00:00.000ZMedical Devices; Neurological Devices; Classification of the Computerized Behavioral Therapy Device for the Treatment of Fibromyalgia Symptomshttps://www.pharmaradar360.com/article/medical-devices-clinical-chemistry-and-toxicology-devices-classification-of-the-60e5ee91ce323bfbPharma Surgeen2026-06-26T00:00:00.000ZMedical Devices; Clinical Chemistry and Toxicology Devices; Classification of the Prognostic Test for Development or Progression of Preeclampsiahttps://www.pharmaradar360.com/article/medical-devices-general-hospital-and-personal-use-devices-classification-of-the-418ff1471f13e3d9Pharma Surgeen2026-06-26T00:00:00.000ZMedical Devices; General Hospital and Personal Use Devices; Classification of the Foam or Gel Chemical Sterilant/High Level Disinfectanthttps://www.pharmaradar360.com/article/agency-information-collection-activities-proposed-collection-comment-request-tim-ee7ed34151674cf3Pharma Surgeen2026-06-26T00:00:00.000ZAgency Information Collection Activities; Proposed Collection; Comment Request; Time and Extent Applications for Nonprescription Drug Productshttps://www.pharmaradar360.com/article/solicitation-for-public-comments-on-the-development-of-an-independent-accreditat-093f9298ad9301ffPharma Surgeen2026-06-26T00:00:00.000ZSolicitation for Public Comments on the Development of an Independent Accreditation System for Certified Community Behavioral Health Clinic Expansion (CCBHC-E) Grant Recipientshttps://www.pharmaradar360.com/article/center-for-scientific-review-notice-of-closed-meetings-1808010f787210ebPharma Surgeen2026-06-26T00:00:00.000ZCenter for Scientific Review; Notice of Closed Meetingshttps://www.pharmaradar360.com/article/tips-to-avoid-dehydration-as-temperatures-rise-60cded32f875d109Pharma Surgeen2026-06-26T00:00:00.000ZTips to Avoid Dehydration as Temperatures Risehttps://www.pharmaradar360.com/article/cleveland-clinic-fairview-hospital-marks-major-milestone-in-expansion-with-toppi-c135cb0d87afa7c7Pharma Surgeen2026-06-26T00:00:00.000ZCleveland Clinic Fairview Hospital Marks Major Milestone in Expansion With Topping Out Ceremonyhttps://www.pharmaradar360.com/article/the-real-world-safety-evaluation-of-the-selective-nav1-8-inhibitor-suzetrigine-d-ab8a63edb5de81dfPharma Surgeen2026-06-26T00:00:00.000ZThe real-world safety evaluation of the selective NaV1.8 inhibitor suzetrigine: disproportionality analysis and flexible empirical bayes signals from FAERS with external triangulationhttps://www.pharmaradar360.com/article/effectiveness-and-safety-of-guipi-mixture-for-the-treatment-of-premature-ventric-2518a40e0cd800f5Pharma Surgeen2026-06-26T00:00:00.000ZEffectiveness and safety of Guipi Mixture for the treatment of premature ventricular contractions (heart-spleen deficiency syndrome): study protocol for a randomized, double-blind, placebo-controlled, multicentre trialhttps://www.pharmaradar360.com/article/a-unified-analytical-method-greenness-score-uamgs-quantifies-how-microscopic-ima-e4595e91eb6891cfPharma Surgeen2026-06-26T00:00:00.000ZA Unified Analytical Method Greenness Score (uAMGS) Quantifies How Microscopic Imaging Is Greener Than Conventional Liquid Chromatographyhttps://www.pharmaradar360.com/article/old-drugs-new-weapons-current-trends-in-repurposing-therapies-against-antimicrob-8cc545a5aeed9c5dPharma Surgeen2026-06-26T00:00:00.000ZOld drugs, new weapons: current trends in repurposing therapies against antimicrobial resistancehttps://www.pharmaradar360.com/article/advancing-women-s-health-through-equity-in-quantitative-sciences-promoting-sex-a-318b4fe38ee798e6Pharma Surgeen2026-06-26T00:00:00.000ZAdvancing women's health through equity in quantitative sciences: promoting sex- and gender-based modeling in clinical trials and real-world studieshttps://www.pharmaradar360.com/article/application-of-immune-checkpoint-inhibitors-in-hepatocellular-carcinoma-a-landsc-6ea266e754ba887fPharma Surgeen2026-06-26T00:00:00.000ZApplication of immune checkpoint inhibitors in hepatocellular carcinoma: a landscape analysis of clinical trial databaseshttps://www.pharmaradar360.com/article/reduction-of-fentanyl-induced-cough-by-low-dose-nalbuphine-pretreatment-during-i-2b84b273dd66f1bcPharma Surgeen2026-06-26T00:00:00.000ZReduction of fentanyl-induced cough by low-dose nalbuphine pretreatment during induction of general anesthesia in children: a randomized controlled trialhttps://www.pharmaradar360.com/article/current-positioning-and-future-development-of-belantamab-mafodotin-and-other-ant-29fb49578b7acf61Pharma Surgeen2026-06-26T00:00:00.000ZCurrent positioning and future development of belantamab mafodotin and other antibody-drug conjugates to treat multiple myelomahttps://www.pharmaradar360.com/article/the-safety-and-efficacy-of-human-umbilical-cord-mesenchymal-stem-cell-for-acute-e65d2cbda0520670Pharma Surgeen2026-06-26T00:00:00.000ZThe safety and efficacy of human umbilical cord mesenchymal stem cell for acute respiratory distress syndrome: an open-label and multicenter phase 1 clinical trialhttps://www.pharmaradar360.com/article/cellular-senescence-in-periodontal-ageing-molecular-mechanisms-clinical-implicat-7fed69d660979fe9Pharma Surgeen2026-06-26T00:00:00.000ZCellular Senescence in Periodontal Ageing: Molecular Mechanisms, Clinical Implications and Emerging Therapeutic Strategieshttps://www.pharmaradar360.com/article/research-advances-and-clinical-prospects-of-cigb-300-a-novel-ck2-targeted-peptid-6e2af65ad72bf812Pharma Surgeen2026-06-26T00:00:00.000ZResearch advances and clinical prospects of CIGB-300, a novel CK2-targeted peptide inhibitor for cancer therapyhttps://www.pharmaradar360.com/article/jurisdiction-on-trial-law-morality-and-power-in-late-medieval-italy-the-domodoss-ba60d81b288c24f5Pharma Surgeen2026-06-26T00:00:00.000ZJurisdiction on Trial: Law, Morality, and Power in Late Medieval Italy. The Domodossola Case (1318–1321)https://www.pharmaradar360.com/article/bacterial-infection-and-sepsis-associated-inflammation-mechanistic-insights-and-6d9e9026bb04e2c6Pharma Surgeen2026-06-26T00:00:00.000ZBacterial infection and sepsis-associated inflammation: Mechanistic insights and emerging clinical perspectiveshttps://www.pharmaradar360.com/article/mesenchymal-stem-cells-and-their-exosomes-in-cardiac-repair-advances-and-future-dc429e11c243a8e3Pharma Surgeen2026-06-26T00:00:00.000ZMesenchymal Stem Cells and Their Exosomes in Cardiac Repair: Advances and Future Directionshttps://www.pharmaradar360.com/article/clinical-profile-and-etiological-spectrum-of-scleritis-in-a-tertiary-care-centre-2165c3f502b38ce4Pharma Surgeen2026-06-26T00:00:00.000ZClinical Profile and Etiological Spectrum of Scleritis in a Tertiary Care Centrehttps://www.pharmaradar360.com/article/management-0f-fingertip-amputations-contemporary-surgical-options-235e8dac5248f895Pharma Surgeen2026-06-26T00:00:00.000ZManagement 0f Fingertip Amputations: Contemporary Surgical Optionshttps://www.pharmaradar360.com/article/clinical-optical-bench-and-model-based-assessment-of-an-extended-depth-of-focus-fb80bdc65311e0fcPharma Surgeen2026-06-26T00:00:00.000ZClinical, optical bench, and model-based assessment of an extended depth-of-focus versus a monofocal intraocular lens: A through-focus comparative studyhttps://www.pharmaradar360.com/article/beyond-skills-reimagining-clinical-education-for-a-transformative-future-2896b8b071127ac8Pharma Surgeen2026-06-26T00:00:00.000ZBeyond skills: Reimagining clinical education for a transformative futurehttps://www.pharmaradar360.com/article/literature-based-peer-support-to-enhance-self-acceptance-among-university-studen-3800d64fae6bd80cPharma Surgeen2026-06-26T00:00:00.000ZLiterature-Based Peer Support to Enhance Self-Acceptance Among University Studentshttps://www.pharmaradar360.com/article/digital-diseases-cb1a91384ca21b43Pharma Surgeen2026-06-26T00:00:00.000ZDigital Diseaseshttps://www.pharmaradar360.com/article/the-evolution-of-nerve-sparing-radical-prostatectomy-mechanisms-of-injury-econom-d5f1f5c8878159c8Pharma Surgeen2026-06-26T00:00:00.000ZThe Evolution of Nerve-Sparing Radical Prostatectomy: Mechanisms of Injury, Economic Impact, and the Potential Value of Intraoperative Nerve Visualization